You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameAnti-SRC3 antibody [0.T.198]See all SRC3 primary antibodies ...
  • Description
    Mouse monoclonal [0.T.198] to SRC3
  • Tested applicationsWB, IP, IHC-P more details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Fusion protein, corresponding to amino acids 605-1294 of Human NCOA3.

  • Positive controlRIPA lysates from BG-1 ovarian cancer cells.
  • General notesAliquots are stable for at least 24 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications

Our Abpromise guarantee covers the use of ab14139 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
WB WB: 1/1000. Detects a band of approximately 150 kDa (predicted molecular weight: 170 kDa).
IP IP: Use 10µl for 10500 cells.
IHC-P IHC-P: Use at an assay dependent dilution.

Target

  • FunctionNuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Plays a central role in creating a multisubunit coactivator complex, which probably acts via remodeling of chromatin. Involved in the coactivation of different nuclear receptors, such as for steroids (GR and ER), retinoids (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR) and prostanoids (PPARs). Displays histone acetyltransferase activity. Also involved in the coactivation of the NF-kappa-B pathway via its interaction with the NFKB1 subunit. Interacts with PSMB9.
  • Tissue specificityWidely expressed. High expression in heart, skeletal muscle, pancreas and placenta. Low expression in brain, and very low in lung, liver and kidney.
  • Sequence similaritiesBelongs to the SRC/p160 nuclear receptor coactivator family.
    Contains 1 basic helix-loop-helix (bHLH) domain.
    Contains 1 PAS (PER-ARNT-SIM) domain.
  • DomainContains three Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs. Motifs 1 and 2 are essential for the association with nuclear receptors, and constitute the RID domain (Receptor-interacting domain).
  • Post-translational
    modifications
    Acetylated by CREBBP. Acetylation occurs in the RID domain, and disrupts the interaction with nuclear receptors and regulates its function.
    Methylated by CARM1.
    Phosphorylated by IKK complex. Regulated its function.
  • Cellular localizationCytoplasm. Nucleus. Mainly cytoplasmic and weakly nuclear. Upon TNF activation and subsequent phosphorylation, it translocates from the cytoplasm to the nucleus.
  • Target information above from: UniProt accession Q9Y6Q9 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
      ACTR antibodyAIB 1 antibodyAIB-1 antibody
      AIB1 antibodyAmplified in breast cancer 1 antibodyAmplified in breast cancer 1 protein antibodybHLHe42 antibodyCAGH 16 antibodyCAGH16 antibodyCBP interacting protein antibodyCBP-interacting protein antibodyClass E basic helix-loop-helix protein 42 antibodyCTG 26 antibodyCTG26 antibodyKAT13B / AIB1 antibodyMGC141848 antibodyNCOA 3 antibodyNCOA 3 antibodyNCoA-3 antibodyNCOA3 antibodyNCOA3_HUMAN antibodyNuclear receptor coactivator 3 antibodyNuclear receptor coactivator 3 antibodypCIP antibodypCIP antibodyRAC 3 antibodyRAC-3 antibodyRAC3 antibodyReceptor associated coactivator 3 antibodyReceptor-associated coactivator 3 antibodySRC 3 antibodySRC-3 antibodySRC3 antibodySteroid receptor coactivator protein 3 antibodySteroid receptor coactivator protein 3 antibodyThyroid hormone receptor activator molecule 1 antibodyThyroid hormone receptor activator molecule 1 antibodyTNRC14 antibodyTNRC16 antibodyTRAM 1 antibodyTRAM-1 antibodyTRAM1 antibody
    see all

Anti-SRC3 antibody [0.T.198] images

  • Superficial spreading type level IV malignant melanoma from the skin of the back, with microsatellite formation, possible lymphatic vascular invasion, low mitotic rate and moderate tumor infiltrating lymphocytes. Ab14139 used at a dilution of 1:25.

References for Anti-SRC3 antibody [0.T.198] (ab14139)

This product has been referenced in:
  • Gould Rothberg BE  et al. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101:452-74 (2009). Read more (PubMed: 19318635) »
  • Rangel J  et al. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J Clin Oncol 24:4565-9 (2006). IHC-P ; Human . Read more (PubMed: 17008696) »

See all 2 Publications for this product

Product Wall

Displaying 1 - 1 of 1 results for Abreviews and Q&A

Thank you for your enquiry. I am sorry I couldn't get any information about the specific antigen retrival method used for the image seen on the datasheet. I would assume a general antigen retrival method was used. Please refer to our website's IHC-P pr...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"